Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess word is getting out with XXII highlighted on Reddit/Robinhood: “3 Reddit Penny Stocks To Buy On Robinhood (*For Probably Not Much Longer - my edit!) Under $5
Read in Entrepreneur: https://apple.news/Am7H4zgBITa-RHCs-n2LL-g
XXII highlighted in “Reddit Penny Stocks To Buy On Robinhood Under $5” (but possibly not below $5 for long!)
Read in Entrepreneur:
https://apple.news/Am7H4zgBITa-RHCs-n2LL-g
Here’s another purported Altria investor who has read the scientific studies and has invested in XXII and the probability of the reduced nicotine mandate moving forward:
https://public.com/p/5cbe6cf0-e804-44cd-9e05-8106b09c42d5
Here’s an Altria investor who has actually done some underlying research and understands that VLN studies show that a 95% reduction in nicotine results in FEWER cigarettes smoked and MORE quit attempts:
https://seekingalpha.com/article/4420528-nicotine-reduction-creates-risk-for-altria?mail_subject=mo-proposed-nicotine-reduction-creates-dire-risk-for-altria&utm_campaign=rta-stock-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha
FYI - Link to a bunch of NIH and other private studies showing that reducing nicotine in cigarettes does NOT result in compensatory smoking (i.e., “current smokers will simply smoke more cigarettes to get the same nicotine fix”) but does result in an increase in quit attempts.
Big Tobacco and its backers/analysts will continue to try to deflect by saying that (1) “VLN is not technically feasible”; (2) “VLN will merely result in smokers smoking MORE cigs”; etc. THAT’S NOT WHAT THE SCIENCE SHOWS; CALL THESE PEOPLE OUT. FDA says it will “follow the science”; I hope it does, as it should. Nice also to give people who decide to try smoking the option to smoke but not get addicted, and nice to give smokers a better option of being able to quit.
https://www.xxiicentury.com/vln-clinical-studies/published-clinical-studies-on-very-low-nicotine-content-vlnc-cigarettes
Sorry - wrong link in riot post - here’s the correct one: The conclusions from this recent study will further take the wind out of Altria’s and Big Tobacco’s sails and make it more likely that the FDA will “follow the science”: “Conclusions: Our results extend previous findings that switching to VLNC cigarettes disrupts the relationship between affect and cigarette consumption by showing that either gradually or immediately reducing cigarette nicotine content achieves this disruption. These findings provide further evidence that switching to VLNC cigarettes reduces nicotine-related reinforcement of cigarette smoking.”
https://pubmed.ncbi.nlm.nih.gov/31701153/
Recent PubMed publication which will take further wind out of Altria’s (and Big Tobacco’s) sails: “Conclusions: Our results extend previous findings that switching to VLNC cigarettes disrupts the relationship between affect and cigarette consumption by showing that either gradually or immediately reducing cigarette nicotine content achieves this disruption. These findings provide further evidence that switching to VLNC cigarettes reduces nicotine-related reinforcement of cigarette smoking.”
?
https://www.bloomberg.com/news/articles/2021-04-19/cigarette-makers-plunge-on-news-that-u-s-may-curb-nicotine
I think we can safely assume that XXII also stands ready to help THE ENTIRE U.S. TOBACCO MARKET(!!) with Biden’s/the FDA’s re-vamped proposal to mandate Very Low Nicotine tobacco...
https://finance.yahoo.com/news/22nd-century-stands-fully-prepared-215600267.html
Here again are four former (bi-partisan) FDA Commissioners advocating last month for the FDA to move forward with its proposed reduced nicotine mandate for the U.S. (which would now follow New Zealand):
https://www.statnews.com/2021/03/12/former-fda-commissioners-push-strong-tobacco-regulation/
New Zealand plans to slash nicotine in cigarettes by 95 percent. FDA should be leading the world in this endeavor, as it proposed in 2017, but following NZ’s example is better than nothing:
https://www.newshub.co.nz/home/politics/2021/04/smokefree-2025-government-plans-to-slash-nicotine-in-cigarettes-by-95-percent.html
New Zealand’s Ministry of Health recently published this plan to go “Smokefree by 2025”. One of the recommendations for adoption is to reduce the amount of nicotine in cigarettes to minimally or non-addictive levels:
https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/smokefree-aotearoa-2025
New Zealand’s Ministry of Health recently published this plan to go “Smokefree by 2025”; one of the recommendations for adoption is to reduce the amount of nicotine in cigarettes to minimally or non-addictive levels:
https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/smokefree-aotearoa-2025
Here’s the New Zealand medical journal letter from 2016 specifically recommending that NZ mandate use of XXII’s VLN cigarettes:
https://www.biospace.com/article/releases/-b-i-new-zealand-medical-journal-i-b-publishes-letter-recommending-22nd-century-group-inc-s-very-low-nicotine-cigarettes-as-important-smoking-r/
Dawson James analyst report on 22nd Century - $7 price target:
https://files.constantcontact.com/fdcb5758701/6cab4d04-f072-4717-80a6-68d91f8e7eda.pdf
I don’t know - thinking it could be sooner than that as there seems to be a lot of momentum right now around the menthol ban. Could wind up being a huge bonus for XXII.
Imagine if the FDA banned all addictive menthol cigarettes, but approved XXII’s VLN menthol MRTP - the rationale being based upon (among other things) libertarian values - if people want to smoke menthol cigarettes, they should have that choice - but the gov’t shouldn’t allow companies to addict people to their choices.
Advocates are hoping that President Biden will soon come out in favor of banning mint-flavored cigarettes and other tobacco products.
https://www.nytimes.com/2021/03/22/health/methol-smoking-ban.html?smid=em-share
Ummm, no - it’s not related at all.
A bipartisan group of former FDA commissioners support limiting nicotine levels in cigarettes to non-addicted levels. We agree. It will prevent kids from becoming addicted and help smokers quit. https://t.co/ynWSdNVEjD
— Campaign for Tobacco-Free Kids (@TobaccoFreeKids) March 15, 2021
The re-prioritized reduced nicotine mandate for all tobacco products is looking likelier and likelier under Biden. This alone would easily push XXII’s share price into double digits.
https://www.theatlantic.com/ideas/archive/2020/12/easy-way-to-quit-smoking/617305/
Thanks for the confirmation. So Mish has used 1/4 of his 2021 salary on this open market stock purchase. Seems to me like he’s pretty confident.
Becerra as HHS Secretary is GREAT for XXII. The link to his letter from July 2018 commenting on the proposed reduced nicotine mandate is below. Note his response to the FDA’s question as to “whether a 2-year, 4-year, or 6-year timeframe for the effective date of the [reduced nicotine mandate] rule would be appropriate?: Becerra’s response: “...FDA should move with deliberate speed and should not provide for an extended timeframe for the effective date. Further, the scale of the anticipated public health benefits of the proposed [nicotine reduction] standard counsel that there should be no unnecessary delay in realizing those gains.”
Note that Becerra’s comment letter also advocates that the proposed reduced nicotine standard should apply to ALL tobacco products, not merely combustible cigarettes.
The right people are in place to make this happen. XXII (and the public’s health) will be a HUGE beneficiary.
https://oag.ca.gov/sites/all/files/agweb/pdfs/tobacco/ag-nicotine-standard-letter-fda-071618.pdf?
Another reminder of what re-prioritization of the FDA’s reduced nicotine mandate under Biden/Becerra/Woodcock would mean - not only for public health but also for XXII:
https://www.theatlantic.com/ideas/archive/2020/12/easy-way-to-quit-smoking/617305/
With Xavier Becerra’s nomination for HHS Secretary moving forward this week, here again is the letter from 2018 he and other State AGs sent to the FDA supporting the FDA’s proposed reduced nicotine mandate. It wouldn’t be surprising if the FDA re-prioritizes the mandate following Becerra’s confirmation and Dr. Woodcock being moved from “acting” FDA Commissioner to named FDA Commissioner.
https://oag.ca.gov/sites/all/files/agweb/pdfs/tobacco/ag-nicotine-standard-letter-fda-071618.pdf?
Bipartisan group of former FDA commissioners pushes for strong tobacco regulation:
“Certainly if a Republican administration can begin a process to regulate nicotine in combustible tobacco, I suspect that it's going to be taken forward by a Democratic administration.”
https://www.statnews.com/2021/03/12/former-fda-commissioners-push-strong-tobacco-regulation/
Link to former FDA Commissioners’ panel discussion today (where they discuss the probability of the FDA re-prioritizing the reduced nicotine mandate):
https://www.youtube.com/watch t=1381&v=B6ebCtgMads&feature=youtu.be
FDA podcast was incredibly positive - all 4 former FDA Commissioners came out strongly in favor of the Biden Administration/FDA moving forward with the reduced nicotine mandate.
Bradley Woods/analyst report link (March 12, 2021- post conference call):
https://files.constantcontact.com/e364e352801/b4527f06-09da-4297-a6e5-53f1ade1a5e0.pdf
Post-call excerpt from Bradley Woods analyst report:
XXII: 22nd Century Group, Inc.
?Company Update -- Buy | $7 Target
March 12, 2021
Equity Research Company Note
Company Data
Price: $2.70
52-Week Range: $0.55-$4.66
Mkt. Cap ($m): $403.9
Shares (m): 149.6
Expect Multiple Catalysts this Year. Reiterate Buy.
We expect multiple catalysts this year can drive 22 nd Century shares higher. The most likely near-term catalyst is approval of the company’s MRTP application with the FDA. Second, the company believes it can begin monetizing its hemp intellectual property this year with one or more licensing deals of plants with specific combinations of cannabinoids. The revivification of the low-nicotine mandate is possible this year. Also, the company will announce development of a third, plant-based franchise after its MRTP application is approved.
It has been just over a year since the company presented to the Tobacco Products Scientific Advisory Committee (TPSAC) and with the pandemic receding, and a new administration implementing its policies we believe conditions are favorable for approval. The company is committed to a commercial launch of VLN cigarettes within 90 days of MRTP approval and is in active discussion with retailers and distributors. The initial stage will be to select markets to test customer acceptance, pricing, and marketing. This will continue for a few months and recalibrated as the roll-out expands.
Very good c/call. Looking forward to HHS Secretary being confirmed and FDA head settling in.
In other news, Mexico moving closer to decriminalizing marijuana should help XXII.
https://www.google.com/amp/s/mobile.reuters.com/article/amp/idUSKBN2B22UT
Another new patent assigned to 22nd Century:
https://patents.justia.com/assignee/22nd-century-limited-llc
(Not sure if someone already posted this today?)
Thanks for sharing this. I signed up for the panel discussion and submitted a question asking the panel’s thoughts on whether they (primarily Gottlieb) thinks that the reduced nicotine mandate will or should be re-prioritized soon under the Biden Administration.
One example of why, under the Biden Adminstration, smoking-related issues will once again be more of a priority, which bodes well for the reduced nicotine mandate also being re-prioritized:
https://abcnews.go.com/Health/wireStory/health-panel-expands-lung-cancer-screening-smokers-76341863
Excerpt from Bradley Woods research report: Q4 Preview
22nd Century reports Q4 results on Thursday followed by an 8:00AM Eastern conference call. For the quarter we are estimating $6 million in revenue and an EBITDA loss of $3.9 million. We reiterate our Buy recommendation and $7 price target.
The two major catalysts for the shares are approval of the company’s MRTP application and the revivification of the low-nicotine mandate. We remain optimistic on both and expect the MRTP to be approved in the coming months, while the low-nicotine mandate may need approval of a new FDA commissioner. President Biden has yet to nominate an FDA commissioner and it will probably take 30 to 60 days after the nomination for approval. There could then be additional time spent as the new commissioner sets priorities. The low-nic goal is still alive, as indicated by Mitchell Zeller, Director of the FDA’s Center for Tobacco Products at the Tobacco and Nicotine Products Regulation and Policy Conference held in October 2020.